{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:01:54Z","timestamp":1790398914771,"version":"4.1.0"},"reference-count":79,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2018.9583","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T08:48:15Z","timestamp":1539679695000},"source":"Crossref","is-referenced-by-count":32,"title":["Patient\u2011derived xenograft mouse models: A high fidelity tool for individualized medicine (Review)"],"prefix":"10.3892","author":[{"given":"Cong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Acute Abdomen Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pixu","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning 116044, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuwen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Acute Abdomen Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"key20200714084726_b1-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/clpt.2013.117","article-title":"Clinical approval success rates for investigational cancer drugs","volume":"94","author":"DiMasi","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"key20200714084726_b2-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20200714084726_b3-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bcp.2014.06.008","article-title":"Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology","volume":"91","author":"Rosfjord","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"key20200714084726_b4-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","article-title":"Van tine Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma","volume":"32","author":"Chawla","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20200714084726_b5-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","article-title":"Hypoxia-inducible transcription factors, and renal cancer","volume":"69","author":"Sch\u00f6del","year":"2016","journal-title":"Eur Urol"},{"key":"key20200714084726_b6-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"key20200714084726_b7-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aad0862","article-title":"Cancer. Tumor angiogenesis from foe to friend","volume":"349","author":"Rivera","year":"2015","journal-title":"Science"},{"key":"key20200714084726_b8-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fendo.2014.00192","article-title":"Estrogen biosynthesis and action in ovarian cancer","volume":"5","author":"Mungenast","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20200714084726_b9-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1016\/j.cellsig.2014.07.034","article-title":"Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment","volume":"26","author":"Nwabo Kamdje","year":"2014","journal-title":"Cell Signal"},{"key":"key20200714084726_b10-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"key":"key20200714084726_b11-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2013.11.004","article-title":"Molecularly targeted cancer therapy: Some lessons from the past decade","volume":"35","author":"Huang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"key20200714084726_b12-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrd2110","article-title":"The mighty mouse: Genetically engineered mouse models in cancer drug development","volume":"5","author":"Sharpless","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key20200714084726_b13-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2014.11.023","article-title":"OVA12, a novel tumor antigen, promotes cancer cell growth and inhibits 5-fluorouracil-induced apoptosis","volume":"357","author":"Zhang","year":"2015","journal-title":"Cancer Lett"},{"key":"key20200714084726_b14-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/pros.23057","article-title":"Synergistic anticancer efficacy of MEK inhibition and dual PI3K\/mTOR inhibition in castration-resistant prostatecancer","volume":"75","author":"Park","year":"2015","journal-title":"Prostate"},{"key":"key20200714084726_b15-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"key20200714084726_b16-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/0008-5472.CAN-14-2004","article-title":"A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma","volume":"75","author":"Wykosky","year":"2015","journal-title":"Cancer Res"},{"key":"key20200714084726_b17-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.semcdb.2014.04.003","article-title":"Cancer mouse models: Past, present and future","volume":"27","author":"Khaled","year":"2014","journal-title":"Semin Cell Dev Biol"},{"key":"key20200714084726_b18-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1073\/pnas.0712184105","article-title":"A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging","volume":"105","author":"Hajitou","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200714084726_b19-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1158\/0008-5472.CAN-12-1060","article-title":"Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"key20200714084726_b20-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1158\/1535-7163.MCT-14-0083-T","article-title":"Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer","volume":"13","author":"Kung","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20200714084726_b21-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/bcj.2015.19","article-title":"A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia","volume":"5","author":"Saland","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20200714084726_b22-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","article-title":"Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models","volume":"16","author":"Santel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b23-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2015.06.024","article-title":"Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors","volume":"367","author":"Lee","year":"2015","journal-title":"Cancer Lett"},{"key":"key20200714084726_b24-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"key20200714084726_b25-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/9780470942390.mo120140","article-title":"Establishment of patient-derived xenograft (PDX) models of human breast cancer","volume":"3","author":"Zhang","year":"2013","journal-title":"Curr Protoc Mouse Biol"},{"key":"key20200714084726_b26-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"e79874","DOI":"10.1371\/journal.pone.0079874","article-title":"Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS One"},{"key":"key20200714084726_b27-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jss.2013.11.010","article-title":"Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors","volume":"187","author":"Cho","year":"2014","journal-title":"J Surg Res"},{"key":"key20200714084726_b28-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","article-title":"Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution","volume":"518","author":"Eirew","year":"2015","journal-title":"Nature"},{"key":"key20200714084726_b29-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/hmg\/ddg078","article-title":"Comparison of the genomes ofhuman and mouse lays the foundation of genome zoology","volume":"12","author":"Emes","year":"2003","journal-title":"Hum Mol Genet"},{"key":"key20200714084726_b30-ol-0-0-9583","first-page":"149","article-title":"The nude mouse: A model of deficient T-cell function","volume":"7","author":"Pelleitier","year":"1975","journal-title":"Methods Achiev Exp Pathol"},{"key":"key20200714084726_b31-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s001090050150","article-title":"Immune-deficient SCID and NOD\/SCID mice models as functional assays for studying normal and malignant human hematopoiesis","volume":"75","author":"Lapidot","year":"1997","journal-title":"J Mol Med"},{"key":"key20200714084726_b32-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J Immunol"},{"key":"key20200714084726_b33-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: Building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"key20200714084726_b34-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymeth.2010.01.027","article-title":"Circulating tumour cells in clinical practice: Methods of detection and possible characterization","volume":"50","author":"Alunni-Fabbroni","year":"2010","journal-title":"Methods"},{"key":"key20200714084726_b35-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b36-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"180ra48","DOI":"10.1126\/scitranslmed.3005109","article-title":"The Identification and characterization of breast cancer CTCs competent for brain metastasis","volume":"5","author":"Zhang","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20200714084726_b37-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"key20200714084726_b38-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u2018xenopatients\u2019) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"key":"key20200714084726_b39-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2013.08.026","article-title":"Differential drug responses of circulating tumor cells within patient blood","volume":"352","author":"Hughes","year":"2014","journal-title":"Cancer Lett"},{"key":"key20200714084726_b40-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumorcells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat Med"},{"key":"key20200714084726_b41-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"key20200714084726_b42-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2379::AID-CNCR29>3.0.CO;2-T","article-title":"Radiation therapy tolerance limits. For one or for all?-Janeway Lecture","volume":"77","author":"Peters","year":"1996","journal-title":"Cancer"},{"key":"key20200714084726_b43-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-15-0348","article-title":"PET Imaging in head and neck cancer patients to monitor treatment response: A future role for EGFR-targeted imaging","volume":"21","author":"van Dijk","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b44-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.28696","article-title":"Patient-derived xenografts for individualized care in advanced sarcoma","volume":"120","author":"Stebbing","year":"2014","journal-title":"Cancer"},{"key":"key20200714084726_b45-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/1078-0432.CCR-13-3047","article-title":"Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment","volume":"20","author":"Garralda","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b46-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ijc.28021","article-title":"Comprehensive analysis of PTEN status in breast carcinomas","volume":"133","author":"Jones","year":"2013","journal-title":"Int J Cancer"},{"key":"key20200714084726_b47-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/gim.2013.133","article-title":"Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium","volume":"15","author":"Berg","year":"2013","journal-title":"Genet Med"},{"key":"key20200714084726_b48-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov"},{"key":"key20200714084726_b49-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/1535-7163.MCT-13-0753","article-title":"Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer","volume":"13","author":"Chiron","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20200714084726_b50-ol-0-0-9583","first-page":"1507","article-title":"Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms","volume":"5","author":"Monsma","year":"2015","journal-title":"Am J Cancer Res"},{"key":"key20200714084726_b51-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrclinonc.2015.62","article-title":"Mouse hospital and co-clinical trial project-from bench to bedside","volume":"12","author":"Clohessy","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200714084726_b52-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/molmed.2015.00056","article-title":"A co-clinical platform to accelerate cancer treatment optimization","volume":"21","author":"Lunardi","year":"2015","journal-title":"Trends Mol Med"},{"key":"key20200714084726_b53-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1078-0432.CCR-13-1733","article-title":"Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lungcancer and predict strategies to overcome resistance","volume":"20","author":"Chen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b54-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1172\/JCI78954","article-title":"Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma","volume":"125","author":"Kwong","year":"2015","journal-title":"J Clin Invest"},{"key":"key20200714084726_b55-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.10.010","article-title":"One mouse, one patient paradigm: New avatars of personalized cancer therapy","volume":"344","author":"Malaney","year":"2014","journal-title":"Cancer Lett"},{"key":"key20200714084726_b56-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-11-0061","article-title":"The APL paradigm and the \u2018co-clinical trial\u2019 project","volume":"1","author":"Nardella","year":"2011","journal-title":"Cancer Discov"},{"key":"key20200714084726_b57-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nature10937","article-title":"A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response","volume":"483","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"key20200714084726_b58-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","article-title":"Maintaining tumor heterogeneity in patient-derived tumor xenografts","volume":"75","author":"Cassidy","year":"2015","journal-title":"Cancer Res"},{"key":"key20200714084726_b59-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/onc.2015.94","article-title":"XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer","volume":"35","author":"Morton","year":"2016","journal-title":"Oncogene"},{"key":"key20200714084726_b60-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-12-0372","article-title":"Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer","volume":"18","author":"Julien","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b61-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: An emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"key20200714084726_b62-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-011-1815-5","article-title":"Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts","volume":"133","author":"Cottu","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20200714084726_b63-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"DeRose","year":"2011","journal-title":"Nat Med"},{"key":"key20200714084726_b64-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","article-title":"A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res"},{"key":"key20200714084726_b65-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10549-012-2164-8","article-title":"Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures","volume":"135","author":"Kabos","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20200714084726_b66-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10549-012-2226-y","article-title":"Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors","volume":"135","author":"Petrillo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20200714084726_b67-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"568567","DOI":"10.1155\/2012\/568567","article-title":"Patient-derived xenografts of non small cell lung cancer: Resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells","volume":"2012","author":"Moro","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"key20200714084726_b68-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lungcan.2015.05.018","article-title":"Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration","volume":"89","author":"Nakajima","year":"2015","journal-title":"Lung Cancer"},{"key":"key20200714084726_b69-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-06-0594","article-title":"Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features","volume":"67","author":"Dangles-Marie","year":"2007","journal-title":"Cancer Res"},{"key":"key20200714084726_b70-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-12-1740","article-title":"A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells","volume":"19","author":"Puig","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20200714084726_b71-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1479-5876-11-198","article-title":"Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers","volume":"11","author":"Peng","year":"2013","journal-title":"J Transl Med"},{"key":"key20200714084726_b72-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2353\/ajpath.2010.090873","article-title":"Establishment and genomic characterization of mouse xenografts of human primary prostate tumors","volume":"176","author":"Priolo","year":"2010","journal-title":"Am J Pathol"},{"key":"key20200714084726_b73-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/pros.22939","article-title":"Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice","volume":"75","author":"Wetterauer","year":"2015","journal-title":"Prostate"},{"key":"key20200714084726_b74-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ygyno.2015.05.022","article-title":"Ovarian and cervical cancer patient derived xenografts: The past, present, and future","volume":"138","author":"Boone","year":"2015","journal-title":"Gynecol Oncol"},{"key":"key20200714084726_b75-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"e24420","DOI":"10.1371\/journal.pone.0024420","article-title":"Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis","volume":"6","author":"Bankert","year":"2011","journal-title":"PLoS one"},{"key":"key20200714084726_b76-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.mehy.2012.06.009","article-title":"Personalized primary tumor xenograft model established for the pre-clinical trial to guide postoperative chemotherapy","volume":"79","author":"Han","year":"2012","journal-title":"Med Hypotheses"},{"key":"key20200714084726_b77-ol-0-0-9583","article-title":"Establishment of patient-derived subrenal capsule xenograft of pancreatic cancersin NOD\/SCID mice: Potential models for drug responses of personalized chemotherapy","author":"Xue","year":"2012","journal-title":"Proceedings of the Australian Health and Medical Research Congress (AHMRC)"},{"key":"key20200714084726_b78-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/nprot.2014.108","article-title":"Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing","volume":"9","author":"Pav\u00eda-Jim\u00e9nez","year":"2014","journal-title":"Nat Protoc"},{"key":"key20200714084726_b79-ol-0-0-9583","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jpurol.2013.07.009","article-title":"Establishment of a patient-derived Wilms' tumor xenograft model: A promising tool for individualized cancer therapy","volume":"10","author":"Mohseni","year":"2014","journal-title":"J Pediatr Urol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:44:16Z","timestamp":1594719856000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2018.9583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":79,"URL":"https:\/\/doi.org\/10.3892\/ol.2018.9583","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]}}}